Tag - LUMO

Developments

Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

Lumos Pharma (NASDAQ:LUMO) launched a Phase 2b trial evaluating LUM-201 for the treatment of pediatric growth hormone deficiency (PGHD). PGHD is typically caused by the pituitary gland’s inability to make sufficient...

November 10, 2020

Markets

HCW starts Lumos Pharma at buy; PT $33

H.C. Wainwright initiated coverage of Lumos Pharma (NASDAQ:LUMO) with a “buy” rating and $33 price target. The stock closed at $13.80 on Aug. 3. Analyst Edward White writes that the company’s LUM-201 drug candidate is...

August 4, 2020

Tag - LUMO

Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

HCW starts Lumos Pharma at buy; PT $33

General

More